Institute for Research in Biomedicine
Media and Communications
Homologous recombination (HR) could be deleterious when cells are about to undergo division. The Cejka laboratory at the IRB identified a new PLK1-mediated mechanism, which down-regulates DNA end resection late
Can one single antibody catch them all? Scientists discover antibodies that recognise all SARS-CoV-2 variants and also other coronaviruses that cause human disease. The finding opens the door to the
Melanoma is the most lethal skin cancer, and its incidence, though low, has steadily increased over the last few years. During melanoma progression, tumor cells spread across the body via
Recent years have generated considerable demand for information and interaction between Science and society. In this sense, the open day organized in the new Bios+ building in Bellinzona by IRB,
Bellinzona, Feb. 2, 2023 – Last Feb. 2, the Institute for Research in Biomedicine (IRB) and the Institute of Oncology Research (IOR) had the pleasure of welcoming a delegation of
Bellinzona, January 28, 2023: 25th Allergy and Immunology Update (AIU), Grindelwald, Switzerland. Jonathan Muri, Valentina Cecchinato, Mariagrazia Uguccioni and Davide Robbiani won the Biotest Award 2022 for their outstanding study
Last Nov. 30, in the building of the Bellinzona Institutes of Science (Bios+), the IRB community paid tribute to Prof. Marcus Thelen, who after 22 years at the Institute for
October 7, 2022: Virginia Crivelli won the “Best Poster” Price at the USI BioMed PhD Day with the poster “Human neutralizing antibodies to SARS-CoV-2 mutational coldspots that broadly crossreact with
Responsible for the Communication
Andrea Nava
andrea.nava@irb.usi.ch
+41 58 666 7250
Facebook / Twitter
